Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats metastatic NSCLC. Sold as Tecentriq. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Atezolizumab (sold as Tecentriq), first approved May 18, 2016, with 31 new uses approved and 0 published complete response letters.
First approved: May 18, 2016
Applications: 2
New uses approved: 31
Complete response letters: 0
Medicare spending, 2025: $644M
Orphan exclusivity until: Dec 9, 2029
First approved in the EU: Sep 20, 2017
First approved in Japan: Jan 19, 2018
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 20 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
TecentriqA drug with a new indication and a new dosage for the treatment of unresectable thymic carcinoma. · Chugai Pharmaceutical Co., Ltd. · Dec 22, 2025 · Review report
TecentriqDrugs with a new indication and a new dosage for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma, nasal type. · Chugai Pharmaceutical Co., Ltd. · Sep 19, 2025 · Review report
TecentriqDrugs with a new dosage indicated for the treatment of following diseases: ・Unresectable advanced or recurrent non-small cell lung cancer ・Postoperative… · Chugai Pharmaceutical Co., Ltd. · Sep 19, 2025
TecentriqDrugs with a new indication and a new dosage for the treatment of unresectable alveolar soft part sarcoma. · Chugai Pharmaceutical Co., Ltd. · Feb 20, 2025
TecentriqA drug with a new indication and a new dosage for the postoperative adjuvant treatment for PD-L1-positive non-small cell lung cancer. · Chugai Pharmaceutical Co., Ltd. · May 26, 2022
TecentriqA drug with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. · Chugai Pharmaceutical Co., Ltd. · Dec 25, 2020
TecentriqA drug with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. · Chugai Pharmaceutical Co., Ltd. · Sep 25, 2020
TecentriqA drug with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small-cell lung cancer. · Chugai Pharmaceutical Co., Ltd. · Nov 22, 2019 · Review report
Clinical Trials
408 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA